Neurofibromatosis 2 Clinical Trial
Official title:
Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype
NCT number | NCT02811718 |
Other study ID # | 2013P002605b |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | July 2016 |
Est. completion date | July 2018 |
Verified date | August 2018 |
Source | Massachusetts General Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The aim of this study is to determine, whether the 3RP is feasible, accepted and efficacious
and durable when delivered via Skype to patients with neurofibromatosis type 2 (NF2) who are
deaf or have severe hearing loss using Communication Access Realtime Translation (CART)
and/or American Sign Language (ASL).
This will be a substudy of the IRB-approved protocol #2013P002605. It is the same study
except it is looking at a particular sub-population: patients with NF2 who are hard of
hearing.
Status | Completed |
Enrollment | 45 |
Est. completion date | July 2018 |
Est. primary completion date | June 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: 1. Age 18 or older 2. Can read and speak English at or above the 6th grade level 3. Patients with NF2 who are deaf or have severe hearing loss. Exclusion Criteria: 1. Severe active or untreated major mental illness that would interfere with study participation, to be determined at the discretion of the study investigator (e.g. untreated psychosis or suicidality) 2. Recent (within past 3 months) change in antidepressant medication 3. Use of formal relaxation training (including past participation in a mind-body program), currently or in the past 6 months. 4. Unable or unwilling to sign the informed consent documents 5. Unable or unwilling to complete psychological assessments online via the REDCap system. 6. Unable or unwilling to participate in an intervention delivered via videoconferencing with Skype. 7. Unwilling to use either CART or ASL for communication during the Skype groups. |
Country | Name | City | State |
---|---|---|---|
United States | Massachusetts General Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Massachusetts General Hospital | The Children's Tumor Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Intent to Attend | Measures how likely and how motivated the participants is to attend the next session. | Baseline (week 0) | |
Other | Date of Birth, Age, Gender, Race, Ethnicity, Marital Status, Education Status, Employment Status, and hearing status of subjects with NF2 | This questionnaire asks subjects with NF2 to report their date of birth, age, gender, race, ethnicity, marital status, highest level of education, hearing status, and primary employment status over the last 12 months. | Baseline (week 0) | |
Other | Credibility Questionnaire | Measures how much the participant believes the intervention will work. | Baseline (week 0) | |
Other | Client Satisfaction Questionnaire (CSQ-8) | Measures how satisfied the participant is with the intervention. | Post-intervention (week 8) | |
Primary | Quality of Life (WHOQOL-BREF) | The WHOQOL-BREF comprises of 26 items which measure the following broad domains: physical health, psychological health, social relationships, and environment. The WHOQOL-BREF is a shorter version of the original instrument that may be more convenient for use in large research studies or clinical trials. | Change between Baseline (week 0), Post-intervention (week 8) and Follow Up (week 32 and week 64) | |
Primary | Penn Acoustic Neuroma Quality-of Life Scale (PANQOL) | The PANQOL measures quality of life specifically for patients with NF2. | Change between Baseline (week 0), Post-intervention (week 8) and Follow Up (week 32 and week 64) | |
Secondary | Perceived Stress Scale (PSS-10) | The PSS is a widely used psychological instrument for the measurement of the perception of stress. This 10-itam scale is designed to measure the degree to which situations in one's life are appraised, or considered stressful. The scores range from 0-40, with a higher score indicating higher perceived stress. Items were designed to detect how unpredictable, uncontrollable and overloaded respondents find their lives. | Change between Baseline (week 0), Post-intervention (week 8) and Follow Up (week 32) | |
Secondary | The 14-Item Resiliency Scale (RS-14) | The RS-14 measures stress coping ability in the face of adversity. | Change between Baseline (week 0), Post-intervention (week 8) and Follow Up (week 32) | |
Secondary | Patient Health Questionnaire (PHQ) | The PHQ measures symptoms of depression and functional impairment. | Change between Baseline (week 0), Post-intervention (week 8) and Follow Up (week 32) | |
Secondary | Cognitive and Affective Mindfulness Scale (CAMS) | The CAMS measures the degree to which individuals experience their thoughts and feelings. | Change between Baseline (week 0), Post-intervention (week 8) and Follow Up (week 32) | |
Secondary | Life Orientation Test (LOT) Optimism Scale | The LOT Optimism Scale measures individual differences in generalized optimism versus pessimism. | Change between Baseline (week 0), Post-intervention (week 8) and Follow Up (week 32) | |
Secondary | The Gratitude Questionnaire (GQ-6) | The GQ-6 revised is a 6-item measure that assesses individual differences in the proneness to experience gratitude in daily life. Scores range from 6-42, with a higher score indicating a greater sense of gratitude. | Change between Baseline (week 0), Post-intervention (week 8) and Follow Up (week 32) | |
Secondary | Measure of Current Status (MOCS-A) | The MOCS-A is a 13-item measure assessing participants' current self-perceived status on several skills such as: the ability to relax at will, recognize stress-inducing situations, restructure maladaptive thoughts, be assertive about needs, and choose appropriate coping responses as needed. Responses are made on a 7-point scale with higher scores reflecting higher life satisfaction. | Change between Baseline (week 0), Post-intervention (week 8) and Follow Up (week 32) | |
Secondary | Medical Outcomes Study (MOS) Social Support Survey | The MOS Social Support Survey measures various dimensions of social support. | Change between Baseline (week 0), Post-intervention (week 8) and Follow Up (week 32) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03617276 -
Reliability of Functional Outcome Measures in Neurofibromatosis 2
|
||
Active, not recruiting |
NCT00973739 -
Lapatinib Study for Children and Adults With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors
|
Phase 2 | |
Completed |
NCT00030043 -
An Implant for Hearing Loss Due to Removal of Neurofibromatosis 2 Tumors
|
Phase 1 | |
Recruiting |
NCT05685836 -
89Zr-Bevacizumab PET/CT Imaging in NF2 Patients
|
||
Completed |
NCT00004437 -
Phase II Study of the Multichannel Auditory Brain Stem Implant for Deafness Following Surgery for Neurofibromatosis 2
|
Phase 2 | |
Recruiting |
NCT03406208 -
Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing
|
N/A | |
Suspended |
NCT03095248 -
Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors
|
Phase 2 | |
Completed |
NCT02298270 -
Resiliency Training for Patients With Neurofibromatosis Via Videoconferencing With Skype
|
N/A | |
Recruiting |
NCT01885767 -
Neurofibromatosis (NF) Registry Portal
|
||
Completed |
NCT00863122 -
Concentration and Activity of Lapatinib in Vestibular Schwannomas
|
Early Phase 1 | |
Recruiting |
NCT03079999 -
Study of Aspirin in Patients With Vestibular Schwannoma
|
Phase 2 | |
Terminated |
NCT00911248 -
PTC299 for Treatment of Neurofibromatosis Type 2
|
Phase 2 | |
Enrolling by invitation |
NCT04890132 -
Vestibular Precision: Physiology & Pathophysiology
|
N/A | |
Completed |
NCT01490476 -
Efficacy and Safety Study of RAD001 in the Growth of the Vestibular Schwannoma(s) in Neurofibromatosis 2 (NF2) Patients
|
Phase 2 | |
Active, not recruiting |
NCT00004483 -
NF2 Natural History Consortium
|
N/A | |
Recruiting |
NCT03893643 -
Cutaneous and Mucosal Manifestations of Neurofribromatosis Type 2 in Children Under 15
|
||
Active, not recruiting |
NCT04283669 -
Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas
|
Phase 2 | |
Completed |
NCT02831257 -
AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas
|
Phase 2 |